STOCK TITAN

Nantahala (NASDAQ: VYNE) reports 2,000,000-share stake representing 6.00%

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

VYNE Therapeutics Inc. beneficial ownership disclosure: Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, each may be deemed to beneficially own 2,000,000 shares of common stock, representing 6.00% of the class as of March 31, 2026.

The filing states the shares are held by funds and separately managed accounts under Nantahala's control and that the reporting persons have shared voting and dispositive power over these 2,000,000 Shares.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake disclosed by an investment adviser and its principals.

The submission reports that Nantahala Capital Management, LLC may be deemed beneficial owner of 2,000,000 shares and that Messrs. Harkey and Mack, as managing members, are similarly disclosed. The percentage reported is 6.00% as of March 31, 2026.

Cash‑flow treatment and any intent to act (e.g., acquisition or disposition plans) are not stated in the excerpt; subsequent filings would disclose any change in ownership or purpose.

Shares beneficially owned 2,000,000 shares held by funds and separately managed accounts under Nantahala control
Percent of class 6.00% ownership percentage as of <date>March 31, 2026</date>
Record date March 31, 2026 date used to compute beneficial ownership and percentage
CUSIP 92941V308 identifier for VYNE common stock
Beneficially owned regulatory
"As of March 31, 2026, Nantahala may be deemed to be the beneficial owner of 2,000,000 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive power regulatory
"Shared Dispositive Power 2,000,000.00"
Schedule 13G regulatory
"Item 1. (a) Name of issuer: VYNE Therapeutics Inc."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Nantahala Capital report in VYNE (VYNE)?

Nantahala reports beneficial ownership of 2,000,000 shares, representing 6.00% of the outstanding common stock as of March 31, 2026. The shares are held by funds and separately managed accounts under Nantahala's control.

Do Wilmot B. Harkey and Daniel Mack personally own the reported VYNE shares?

Messrs. Harkey and Mack are reported as managing members and may be deemed beneficial owners of the same 2,000,000 shares. The filing attributes shared voting and dispositive power to each as of March 31, 2026.

What voting and dispositive powers are disclosed for the VYNE shares?

The filing states the reporting persons have 0 sole voting or dispositive power and 2,000,000 shares of shared voting and dispositive power over the reported holdings as of March 31, 2026.

Does the Schedule 13G indicate Nantahala will sell or buy more VYNE shares?

The excerpt does not state any purchase or sale intent. It discloses beneficial ownership and voting/dispositive power; any future transactions or plans would require separate filings or disclosures in later reports.

What CUSIP identifies VYNE common stock in this filing?

The filing lists the CUSIP for VYNE common stock as 92941V308. This identifier corresponds to the class of common stock referenced throughout the Schedule 13G disclosure.





92941V308

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:05/15/2026
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:05/15/2026
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:05/15/2026